Oncotarget
Paclitaxel inhibition of cell migration. A mixed culture of wild-type CHO cells and HAβ3-5 cells was scratched to make a wound and the cells were allowed to migrate for 24 h in the absence or presence of 10 nM paclitaxel. The cells were then stained for α-tubulin (red), HAβ3-tubulin (green), and DNA (blue). See Ganguly et al.
Mycoplasmas and Human prostate cancer: An exciting but cautionary note |
https://doi.org/10.18632/oncotarget.282 Shyh-Ching Lo, and Shien Tsai |
352-355 |
Abstract | PDF | HTML | Order a Reprint |
Proteotoxic stress targeted therapy (PSTT) |
https://doi.org/10.18632/oncotarget.284 Michael Y. Sherman |
356-357 |
Abstract | PDF | HTML | Order a Reprint |
Xenotropic murine leukemia virus-related virus (XMRV) in prostate cancer cells likely represents a laboratory artifact |
https://doi.org/10.18632/oncotarget.287 Jiawen Yang, Partho Battacharya, Ruchi Singhal, and Eugene S. Kandel |
358-362 |
Abstract | PDF | HTML | Order a Reprint |
Netrin-1 overexpression is predictive of ovarian malignancies |
https://doi.org/10.18632/oncotarget.258 Anastasios D. Papanastasiou, Georgios Pampalakis, Dionyssios Katsaros, and Georgia Sotiropoulou |
363-367 |
Abstract | PDF | HTML | Order a Reprint |
Class III β-Tubulin Counteracts the Ability of Paclitaxel to Inhibit Cell Migration |
https://doi.org/10.18632/oncotarget.250 Anutosh Ganguly, Hailing Yang, and Fernando Cabral |
368-377 |
Abstract | PDF | HTML | Supplementary Information | Audiopaper | Order a Reprint |
Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors |
https://doi.org/10.18632/oncotarget.269 Asfar S. Azmi, Sanjeev Banerjee, Shadan Ali, Zhiwei Wang, Bin Bao, Frances WJ Beck, Anthony F. Shields, Philip Philip, Fazlul H. Sarkar, and Ramzi M. Mohammad |
378-392 |
Abstract | PDF | HTML | Supplementary Information | Order a Reprint |
No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis |
https://doi.org/10.18632/oncotarget.278 Katharina Bluemlein, Nana-Maria Grüning, René G. Feichtinger, Hans Lehrach, Barbara Kofler, and Markus Ralser |
393-400 |
Abstract | PDF | HTML | Order a Reprint |
YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention |
https://doi.org/10.18632/oncotarget.276 Alastair H. Davies, and Sandra E. Dunn |
401-406 |
Abstract | PDF | HTML | Order a Reprint |
Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity |
https://doi.org/10.18632/oncotarget.272 Mehdi Mollapour, Shinji Tsutsumi, Yeong Sang Kim, Jane Trepel, and Len Neckers |
407-417 |
Abstract | PDF | HTML | Order a Reprint |
Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link |
https://doi.org/10.18632/oncotarget.277 Simone Fulda |
418-421 |
Abstract | PDF | HTML | Order a Reprint |
c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard |
https://doi.org/10.18632/oncotarget.279 Karoline Kollmann, Gerwin Heller, and Veronika Sexl |
422-427 |
Abstract | PDF | HTML | Order a Reprint |
Copyright © 2019 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC